Elsevier

Respiratory Medicine

Volume 95, Issue 8, August 2001, Pages 670-675
Respiratory Medicine

Regular Article
Eosinophil cationic protein (ECP) in saliva: a new marker of disease activity in bronchial asthma

https://doi.org/10.1053/rmed.2001.1123Get rights and content
Under an Elsevier user license
open archive

Abstract

Eosinophil cells play a crucial role in the pathogenesis of asthma, and concentration of eosinophil cationic protein (ECP) in serum has been used to monitor activity of the disease. Our aim was to determine the feasibility and usefulness of measuring ECP in saliva and to use it as a marker of the disease. Thirty-eight patients with asthma and 16 healthy volunteers were included in this study. Repeatability of measurements of ECP in saliva was acceptable [intra-class correlation coefficients (Ri)=0·74 and coefficients of repeatability (CR)=0·37 in five healthy subjects]. Levels of ECP in saliva were higher in asthmatics than in volunteers (P<0·01). There was a significant inverse association between a surrogate variable reflecting disease activity (i.e. change over a few weeks in dose of inhaled corticosteroid required by a change in clinical status of asthma) and a change over the same time period in salivary ECP in 19 patients with stable asthma (r=−0·64, P=0·02). Our findings indicate that levels of salivary ECP are elevated in patients with asthma and associated with presumed activity of disease as recorded by alteration of taken dose of inhaled corticosteroid.

Keywords

eosinophil cationic protein (ECP)
saliva
asthma
bronchial hyper-responsiveness to isocapnic hyperventilation of dry cold air
forced oscillation technique.

Cited by (0)

f1

Correspondence should be addressed to: Birgitta Schmekel, Department of Clinical Physiology, Institute of Medicine and Care, University Hospital, S-58185 Linköping, Sweden. Fax: +46-013 14 59 49.